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The presence of ﬁbrillar protein deposits (amyloid) of human islet amyloid polypeptide (hIAPP) in the pancreatic islets of
Langerhans is thought to be related to death of the insulin-producing islet β-cells in type 2 diabetes mellitus (DM2). The
mechanism of hIAPP-induced β-cell death is not understood. However, there is growing evidence that hIAPP-induced disruption
of β-cell membranes is the cause of hIAPP cytotoxicity. Amyloid cytotoxicity by membrane damage has not only been suggested
for hIAPP, but also for peptides and proteins related to other misfolding diseases, like Alzheimer s disease, Parkinson’s disease, and
prion diseases. Here we review the interaction of hIAPP with membranes, and discuss recent progress in the ﬁeld, with a focus on
hIAPP structure and on the proposed mechanisms of hIAPP-induced membrane damage in relation to β- c e l ld e a t hi nD M 2 .
Copyright © 2008 Lucie Khemt´ emourian et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Long before discovery of the primary structure of the main
component of amyloid in the islets of Langerhans, detailed
ultra structural investigations had revealed that islet amyloid
was often in contact with β-cell membranes [1]. In fact, it
was found that amyloid ﬁbrils were oriented perpendicular
to the membrane of islet β-cells, with some ﬁbril bundles
sticking into membrane invaginations [1]. In 1987, the
main component of islet amyloid was identiﬁed as a 37-
amino acid residue peptide called islet amyloid polypeptide
(IAPP) or amylin [2, 3]. Since then, the presence of IAPP
amyloid at the β-cell membrane, and the concomitant mor-
phological changes of these membranes, has been reported
frequently [4–9]. These reports have contributed to the
current hypothesis that the interaction between IAPP and
cellular membranes could be a cause of IAPP cytotoxicity
and β-cell death in DM2. Before reviewing IAPP-membrane
interactions, we will brieﬂy discuss the present knowledge on
IAPP ﬁbril formation.
2. IAPP FIBRIL FORMATION
2.1. Frommonomertoﬁbril
The amino acid sequence of IAPP varies slightly from
organism to organism [10]. For instance, six residues are
diﬀerent between human IAPP (hIAPP) and mouse IAPP
(mIAPP) (see Figure 1). Importantly, the latter does not
aggregate into amyloid ﬁbrils, and amyloid is generally not
observed in the pancreas of wild-type mice. Nevertheless,
transgenic mouse models that express human IAPP develop
ﬁbrillar deposits and exhibit signs of diabetes [11].
The in vitro aggregation and ﬁbril formation of hIAPP
have been studied extensively in the last years [12–22].
In most of these studies, hIAPP aggregation is initiated
by dilution of, usually synthetic, monomeric hIAPP into
ap h y s i o l o g i c a lb u ﬀer. This results in the “spontaneous”
aggregation of hIAPP monomers into amyloid ﬁbrils, as can
be observed, for example, by electron microscopy. The in
vitro aggregation of hIAPP is typically completed in a few
hours, depending amongst others on peptide concentration2 Experimental Diabetes Research
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hIAPP KCNTATCATQRLANFLVHS SNNFGAILSSTNVGSNTY
mIAPP KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTY
Figure 1: Comparison of the amino acid sequences of human IAPP
(hIAPP) and mouse IAPP (mIAPP). Mouse IAPP diﬀers from the
human peptide by six residues (in red). The rectangle shows the
N-terminal region that is thought to be important for membrane
interactions. The amino acid region suggested to be important for
ﬁbril formation is represented in the underlined.
and presence of lipids [18]. This is signiﬁcantly faster than
the aggregation of most other amyloidogenic peptides. Fibril
formation of IAPP, as well as of some other amyloidogenic
peptides, generally occurs via a nucleation dependent aggre-
gation process [18, 23]. This means that the formation of a
nucleus, usually a slow step, is required for initiation of the
growth of stable ﬁbrils. The nucleus is an ordered oligomeric
hIAPP species that can serve as a template for ﬁbrillar hIAPP.
The kinetics of hIAPP ﬁbril growth can be monitored in
time by the commonly used method of speciﬁc binding
of the ﬂuorescent molecule Thioﬂavin T (ThT) to amyloid
ﬁbrils [24]. A kinetic trace of hIAPP ﬁbril growth shows
a lag phase and a sigmoidal transition that are typical for
ﬁbril growth of amyloidogenic proteins and peptides (see
Figure 2)[ 23]. After dilution of initially monomeric hIAPP
in buﬀer, the thermodynamically unfavourable process of
nucleation occurs, although the initial horizontal baseline
of the ThT curve indicates that no ﬁbrils are formed in the
beginning (lag phase). The sigmoidal increase in the ThT
curve indicates propagation of ﬁbril growth with consump-
tion of monomer. Next to the monomeric and ﬁbrillar states
of hIAPP, several intermediate (oligomeric) states have been
observed, as will be discussed later. Elongation of ﬁbrils
proceeds via addition of monomers or oligomers to both
ﬁbril ends.
2.2. Three-dimensionalmolecularstructureofhIAPP
Thethree-dimensionalstructureofamyloidﬁbrils,andlately
also the structure of monomers and oligomers, has been
the subject of research into the molecular background of
amyloid diseases. However, only little structural information
is available for the IAPP monomer, oligomer, and ﬁbril. In
1992, the ﬁrst, limited information of the three-dimensional
structure of soluble hIAPP was obtained [25]. It was shown
that hIAPP exhibits a random coil structure with small
components of α-helical and β-sheet conformations. Recent
studies conﬁrmed that soluble hIAPP has mainly unordered
backbone structure [26–28]. In contrast, hIAPP dissolved
in the organic solvent triﬂuoroethanol (TFE, a membrane
mimicking solvent) predominantly adopts an α-helical con-
formation [25]. Our observations have indicated that hIAPP
dissolved in TFE initially adopts α-helical structure, before
transforming into β-sheet structure (unpublished results).
These observations suggest that hIAPP could also adopt α-
helical structure in a membrane environment.
hIAPP oligomers or aggregates ranging from dimers up
to 6000 molecules have been reported by several research
groups [7, 29–31]. These oligomers appear to represent
intermediates on the path to ﬁbril formation. There are
recent indications that hIAPP oligomers, in presence of
membranes, exhibit α-helical structure [28]. This is surpris-
ing since it would seem thermodynamically unfavourable
for a monomer with random coil structure to ﬁrst adopt α-
helical structure before changing into β-sheet rich ﬁbrillar
structure. Aggregation intermediates have been observed
for many types of amyloid proteins, such as α-synuclein
and Aβ [32, 33]. Glabe and coworkers have produced
a conformation-dependent antibody that is speciﬁc for
soluble oligomers and does not recognize natively folded
proteins, monomer, or ﬁbrils [34]. They showed that this
antibody recognizes soluble oligomers from a wide variety of
amyloid-forming peptides and proteins such as hIAPP, Prion
106–126, human insulin, Aβ peptide, and polyglutamine,
which suggests that these oligomers might have a common
structure.
The three-dimensional structure of hIAPP ﬁbrils has
beenstudiedbyvarioushigh-resolutiontechniques,likeelec-
tron microscopy, X-ray diﬀraction, electron diﬀraction, and
electron paramagnetic resonance [26, 35–38]. These studies
clearly reveal that hIAPP ﬁbrils contain a signiﬁcant amount
of well-ordered cross-β structure, typical of amyloid ﬁbrils.
During ﬁbril formation, hIAPP undergoes a conformational
change from random coil to a mixture of β-sheet and α-
helical structure [26]. These results are consistent with the
work of Kayed [15], who also measured a random coil to
β-sheet transition for hIAPP ﬁbril formation. hIAPP ﬁbrils
are polymorphic, ranging from thin protoﬁlaments with
a diameter of about 5nm to thicker ﬁbrils with diameter
of up to 15nm that appear to be rope-like bundles of
protoﬁlaments. The predominant type of ﬁbril contains
three protoﬁlaments in a left-handed coil with a pitch of 25–
50nm.
2.3. Whichaminoacidresiduesareimportantfor
hIAPPﬁbrilformation?
Structural studies have shown that amino acid residues 20–
29ofhIAPParecrucialforamyloidformation[12].Aproline
scan of this decamer (hIAPP20–29) has demonstrated that
substitution of a single proline at either position 22, 24 or
at positions 26–28 leads to a drastic reduction of amyloid
formation[39].Notethatthreeofthesixdiﬀerencesbetween
hIAPP and the nonamyloidogenic mIAPP involve a proline,
a residue that is predicted to disrupt ordered structure, like
the β-sheet structure in amyloid ﬁbrils.
Currently, research groups are developing molecules
in an attempt to reduce hIAPP-induced β-cell death by
inhibitinghIAPPﬁbrilformation.Someofthese“inhibitors”
arebasedonsyntheticallymodiﬁedhIAPPpeptidesorhIAPP
fragments that are not able to form ﬁbrils themselves, but are
suggested to bind to, and to stop the elongation of growing
hIAPP ﬁbrils [40–42]. A recent study indicated that a single
amino acid substitution in hIAPP, where Ile on position 26 isLucie Khemt´ emourian et al. 3
replaced by Pro (I26P), yields a potent ﬁbrillization inhibitor
[43].
Althoughresidues20–29playanimportantroleinhIAPP
ﬁbril formation, these may not be the only residues involved.
It has been hypothesized that aromatic-aromatic interac-
tions are also important in hIAPP ﬁbril formation [44].
Human IAPP contains three aromatic residues at positions
15, 23, and 37 (see Figure 1). The aromatic-aromatic and
aromatic-hydrophobic interactions in amyloid formation
were studied using a hIAPP triple mutant [45]. The triple
mutant F15L/F23L/Y37L, lacking aromatic residues, still
forms amyloid ﬁbrils in vitro, indicating that the aromatic
residuesarenotessentialinhIAPPﬁbrilformation.However,
the substitution decreases the rate of ﬁbril formation and
alters the tendency of ﬁbrils to aggregate. Some studies
demonstrate that the amino acid region from residues 11 to
20 is also important for hIAPP ﬁbril formation [46, 47]. A
recent study shows that the hIAPP fragment consisting of
residues 14–20 can form amyloid ﬁbrils [38].
hIAPP contains a single histidine at position 18 (see
Figure 1), which is the only residue in this peptide that has
a charge that depends on pH in a physiological pH range.
Consequently, ﬁbril formation of hIAPP could depend on
the pH. A recent study showed that hIAPP ﬁbril formation
is faster at a lower pH (4.0) than at a higher pH (8.8) [48].
This could be important in a physiological context since in
theβ-cellgranulesofthepancreas,wherehIAPPisstored,the
pH is 5.5, but when hIAPP is released into the extracellular
compartment, it experiences a pH of 7.4 [49].
Another characteristic of hIAPP is the intramolecular
disulﬁde bond between cysteines residues 2 and 7 (see
Figure 1). The disulﬁde does not contribute to the amyloid
ﬁber core structure; however it somehow must play a central
role in the assembly mechanism, since loss of the disulﬁde
signiﬁcantly reduces ﬁbril formation [20].
3. hIAPP AGGREGATION AND FIBRIL FORMATION IN
THE PRESENCE OF MEMBRANES
3.1. Membranephospholipidscatalyse
hIAPPﬁbrilformation
It has been observed that phospholipid membranes promote
the aggregation of hIAPP [28, 50, 51]. In the presence of
phospholipids, the kinetic proﬁle of hIAPP ﬁbril growth
is characterized by a reduction in the lag time resulting
in earlier ﬁbril formation [50]. Cellular membranes could
accelerate hIAPP ﬁbril formation by enhancing nucleation.
The lipid composition may play an important role in
this process, since it has been demonstrated that hIAPP
aggregation is accelerated in the presence of membranes
that contain negatively charged lipids such as 1,2-dioleoyl-
sn-glycero-3-phospho-L-serine (DOPS) or 1,2-Dioleoyl-sn-
Glycero-3-[Phospho-rac-(1-glycerol)](DOPG) [27, 50, 51].
In the presence of such membranes, hIAPP ﬁbril formation
occurs within a few minutes as opposed to a few hours in
the absence of membranes [27, 50]. A membrane-induced
change in the conformation in hIAPP could possibly result
informationand/orstabilizationofanucleus,whichcouldin
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Figure 2: Typical shape of the kinetics of hIAPP ﬁbril formation,
characterized by a lag phase and a sigmoidal transition. The
approximate aggregation state of IAPP is indicated at the various
time points. Fibril formation was induced by adding, at time 0, a
monomeric stock solution of hIAPP in DMSO to buﬀer containing
Thioﬂavin T.
turn result in acceleration of hIAPP ﬁbril formation. Hence,
elucidationoftheconformationofhIAPPininteractionwith
the membrane is an important issue. Knowledge of this con-
formation would give valuable insights into the mechanism
of membrane damage and would aid in developing new
drugs and/or ﬁnding new targets for the treatment of DM2.
3.2. Insightintheconformationof
membrane-interactinghIAPP
Recently, studies have been performed to determine the con-
formation of hIAPP that interacts with model membranes,
that is, large unilamellar vesicles (LUVs) [27, 28, 52]. In
these studies, the LUVs are composed of a combination of
aneutralphospholipid,forinstance,1,2-dioleoyl-sn-glycero-
3-phosphocholine (DOPC), and a negatively charged phos-
pholipid, for instance, 1,2-dioleoyl-sn-glycero-3-phospho-L-
serine (DOPS). In the presence of LUVs, hIAPP initially
displays α-helical structure [27], corresponding with the
structure of hIAPP in the membrane-mimicking solvent
TFE [25]. However, after 40 minutes incubation with LUVs,
the conformation of hIAPP changes to predominantly β-
sheet conformation, characteristic of ﬁbril formation [27].
Recently, the structure of hIAPP in membrane bilayers was
studied using microscopy techniques [53]. It was found
that hIAPP forms pores that are composed of ﬁve sub-
units, in which each subunit is suggested to represent an
hIAPP monomer. This hIAPP morphology was connected to
channel-likebehaviorinplanarbilayers,indicatingthatthese
oligomeric hIAPP pores could incorporate in membranes
and change their barrier properties. Unfortunately, high-
resolution structural information of hIAPP in a membrane
environment is still lacking, mainly because of the instability
of the membrane-interacting hIAPP aggregates. Preliminary
results of our group indicate that hIAPP ﬁbrils grown in
the presence of phospholipids have the same characteristic
structure as ﬁbrils formed in the absence of lipids.4 Experimental Diabetes Research
3.3. Whichresiduesareimportantinthe
interactionwithmembrane?
It is likely that the presence of membranes causes additional
residues in IAPP to be involved in ﬁbril formation, as com-
pared to the situation without membranes. Several residues
that are important for hIAPP-membrane interactions can be
identiﬁed. It can be anticipated that the positively charged
residues, which are all located at the N-terminal part of
hIAPPatpositions1,11,and18(seeFigure 1),willbeimpor-
tant in the interaction of hIAPP with negatively charged
phospholipid membranes. Indeed, there are indications that
hIAPP molecules cluster at the membrane surface, prior to
ﬁbrillogenesis, with their N-termini oriented towards the
membrane [50]. More recently, it was shown that an N-
terminal hIAPP fragment (hIAPP1–19) has a signiﬁcantly
higher ability to insert in phospholipid monolayers than a
fragment from the central, amyloidogenic region of hIAPP
(hIAPP20–29) [54]. These ﬁndings suggest that the N-
terminal part of hIAPP, whilst not signiﬁcantly involved
in hIAPP ﬁbril growth, is important in light of hIAPP-
membrane interactions.
4. MECHANISM OF CYTOTOXICITY
In 1993, work on the amyloidogenic Alzheimer’s related
peptide Abeta had indicated that an amyloidogenic protein
can form ion-selective membrane channels, providing a ﬁrst
hypothesis for the mechanism of amyloid (neuro)toxicity
[55, 56]. The observations that IAPP ﬁbrils are located at
the cellular membrane in the Islets of Langerhans and that
this is accompaniedby alterationsin membranemorphology
[1, 4–9] made researchers hypothesize that the membrane
might be the target of cytotoxic IAPP and that this could
cause death of the insulin producing β-cells, similar to Abeta
neurotoxicity in Alzheimer’s disease. The ﬁrst experimental
evidence that indeed hIAPP can cause membrane disruption
came from work by the Kagan group [57]. It was found from
experiments with planar lipid bilayers that synthetic hIAPP
forms ion-permeable channels “pores” in the membrane,
whereas the nonamyloidogenic mouse IAPP does not form
channels. Mature hIAPP ﬁbrils were found to be less cyto-
toxic; moreover, they did not cause signiﬁcant membrane
disruption in comparison to oligomeric hIAPP [58, 59].
Still, the exact mechanism of hIAPP-induced membrane
disruption is far from understood, and various mechanisms
have been hypothesized during the last 10 years [7, 29,
31, 34, 50, 51, 54, 57, 60–63]. It is, for example, unclear
what the exact nature of the hIAPP species that interacts
with or even disrupts membranes is. The main hypothesis,
based on in vitro evidence, suggests a major role for a
speciﬁc preﬁbrillar hIAPP aggregate, commonly known as
hIAPP oligomer, as the membrane-disrupting species [7, 29,
31, 34, 57, 59, 60, 64]. The various suggested mechanisms
for hIAPP-induced membrane disruption will be discussed
below.
4.1. hIAPPoligomerscausemembrane
damageandarecytotoxic
Recently, it has been suggested that preﬁbrillar aggregates (or
oligomers), formed early during aggregation and not mature
amyloid ﬁbrils are the cytotoxic species in protein misfolding
diseases [65]. Considering amyloid cytotoxicity in DM2, the
prevailing view is that IAPP-induced membrane damage,
and concomitant β-cell death, is caused by cytotoxic hIAPP
oligomers [7, 28, 29, 31, 53, 57, 60, 64]. There are indications
that these oligomers form ion channels [53, 57], as has been
suggested for other amyloidogenic proteins [55, 66]. Other
studies indicate that hIAPP oligomer-induced membrane
damage is not speciﬁc for ions [31] but results in membrane
leakage of molecules with a size of up to 600 Da (Calcein),
indicating a general membrane disruption mechanism by
hIAPP oligomers [28, 51, 59, 63, 67].
Small hIAPP aggregates have been shown to be cytotoxic
incellcultures,andtheseaggregateswerealsoabletodestabi-
lize model membranes [7]. Similarly, oligomeric hIAPP was
found to form membrane pores, allowing molecules with
the size of a calcium ion to pass. These pores disappeared,
and membrane damage decreased, when hIAPP ﬁbrils grew
and oligomers were consumed [29, 60]. Electron microscopy
analysis showed that hIAPP formed spherical shapes with
a diameter of 3 to 20nm, consistent with the presence of
hIAPP oligomers [31, 60]. In a test tube, oligomeric hIAPP
can be prepared under speciﬁc experimental conditions.
Addition of such preparations to human neuroblastoma
cells that were loaded with ﬂuorescent dye resulted in the
cellular leakage of this dye [59]. This indicates that hIAPP
oligomers, when applied to the outside of cells, are cytotoxic
via a general membrane destabilizing eﬀect and not via
a speciﬁc ion pore. The monomeric and ﬁbrillar form of
hIAPP clearly did not have this eﬀect. Later it was also
shown that when applied from the inside of cells, using
cells that overexpress hIAPP, the hIAPP oligomers are also
able to perform their cytotoxic action [64]. Recently, it
has been suggested that ER and mitochondrial membranes
might be the target of cytotoxic hIAPP, resulting in ER stress
and β-cell apoptosis [68]. Moreover, intracellular hIAPP
oligomers were indirectly demonstrated in the pancreatic β-
cells of hIAPP-transgenic mice using an oligomer-speciﬁc
antibody [69]. The latter study also showed that oligomer-
speciﬁc antibodies could not prevent hIAPP-induced β-cell
death, indicating that toxic events might occur inside the
cell.
The exact mechanism of membrane disruption by
hIAPP oligomers is not known. Some groups show that
preassembled hIAPP oligomers disrupt membranes [31,
60], whereas others suggest that hIAPP monomers ﬁrst
interact with the membrane and only then form oligomeric
hIAPP with membrane disrupting capacity [28]. These two
models of membrane damage by hIAPP oligomers have been
schematically depicted in Figure 3.
In conclusion, many observations indicate that hIAPP
oligomers are a likely candidate for inducing cell death. In
contrast, hIAPP ﬁbrils are found not to damage membranes
and could in fact be the result of a physiological mechanismLucie Khemt´ emourian et al. 5
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Figure 3: Simpliﬁed schematic representation of the diﬀerent models of hIAPP-membrane interaction in relation to membrane damage and
hIAPP cytotoxicity. The red rectangles show the toxic species and the red arrows show the toxic processes according to diﬀerent hypotheses.
The black circle represents a phospholipid membrane (vesicle), the grey circles represent hIAPP monomers, and clusters of 4 or more circles
represent hIAPP oligomers and hIAPP ﬁbrils, respectively. Membrane damage is schematically indicated by the grey arrows. Model (1)
includestwosteps:(i)formationofsolublehIAPPoligomers,(ii)interactionofthetoxicoligomerswiththemembraneleadingtomembrane
damage.Model(2)includesthreesteps:(i)bindingofmonomeric,randomcoilhIAPPtothemembraneandfoldingtoα-helix,(ii)oligomer
formation of membrane-bound hIAPP, and (iii) interaction of the toxic hIAPP oligomer with the membrane leading to membrane damage.
Model (3) includes 3 steps: (i) interaction of monomeric and possibly oligomeric hIAPP to the membrane, (ii) growth of hIAPP ﬁbrils at the
membrane (red arrows) leading to a forced change in membrane morphology and concomitant membrane disruption, and (iii) detachment
of mature ﬁbrils from distorted membrane.
inwhichtoxic oligomerspeciesaredisposed ofinanontoxic,
ﬁbrillar form.
4.2. Membranedamagebyﬁbrilgrowth
atthemembrane
In addition to the hypothesis that oligomers are the toxic
species, recent reports suggest also other mechanisms for
hIAPP cytotoxicity. One such hypothesis is that membrane
damage is not caused by a speciﬁc hIAPP species, such as an
oligomer, but by the process of ﬁbril growth at the cellular
membrane. There are several recent indications that growth
of hIAPP ﬁbrils at the membrane can cause membrane dam-
age.Inthismodel,theinitialstepsoftheinteractionofhIAPP
with membranes are adsorption, followed by insertion of
hIAPPintothemembrane,eitherasmonomerorasoligomer
(see Figure 3). The interaction of monomeric hIAPP with
membranes is likely as monomeric hIAPP has a strong
tendency to insert in phospholipid monolayers [52, 54].
In the next step, interactions of membrane-located hIAPP
species with each other, or with hIAPP species in solution,
lead to growth of ﬁbrils at the membrane (model 3 in
Figure 3).Themechanismofmembranedamagecouldentail
growth of a rigid hIAPP ﬁbril on a ﬂexible phospholipid
bilayer, which would result in a forced change in membrane
curvature. This change in membrane curvature leads to
deformation of the shape of the membrane. Interestingly,
disruption, blebbing and vesicle budding of cell membranes
in the presence of synthetic [5, 7, 9] and cell-derived hIAPP
[6, 8, 70] have been noticed in many studies. Our recent
results indicate that the kinetics of membrane damage is
very similar to the kinetics of ﬁbril formation (see Figure 2).
Both processes, ﬁbril formation and membrane damage,
were characterized by the presence of a lag phase and a
strong enhancing eﬀect on the kinetics upon the addition of
seeds [71]. In case of the Alzheimer’s disease-related Abeta
peptide, it has been suggested recently that not a particular
species but ongoing amyloid ﬁbrillogenesis is responsible
for membrane damage [72]. Together, these notions suggest
that a cytotoxic mechanism based on ﬁbril growth at
the membrane could represent a common mechanism for
amyloid-inducedcelldeath.Finally,anotherfactorthatcould
contributetomembranedamagebyﬁbrilgrowthisuptakeof
membrane lipids in amyloid, a phenomenon that has been
observed, both in vitro [51, 73, 74] and in vivo [75].
5. INITIATION OF HARMFUL IAPP-MEMBRANE
INTERACTIONS IN DM2
Since the combination of hIAPP and membranes in non-
diabetic people does not normally result in β-cell death;
certain DM2-related conditions should exist that initiate
hIAPP-induced membrane damage. An increase in the level
of hIAPP, which is coproduced and cosecreted with insulin,
in a state of insulin resistance, could initiate hIAPP ﬁbril
formation. More speciﬁc, an altered ratio of insulin to
hIAPP, as observed in diabetic patients [16], could lead to a
decrease of the inhibitory eﬀect of insulin on hIAPP amyloid6 Experimental Diabetes Research
ﬁbril formation. This inhibitory eﬀect of insulin on hIAPP
ﬁbril formation has been observed in vitro [76–78]. On the
other hand, a changing lipid composition of the β-cells, in
particular an increase in negatively charged lipids as inferred
fromstudieswithmouseandratmodelsforDM2[79],could
also trigger an increase in hIAPP-membrane interactions. In
vitro studies show that negatively charged lipids increase the
rate of hIAPP ﬁbril formation [27, 50] and also enhance
hIAPP-induced membrane damage [28, 51]. The membrane
itself could promote hIAPP growth by increasing the local
concentration of (membrane bound) hIAPP and/or by pro-
moting a speciﬁc orientation or conformation of the peptide
that makes hIAPP molecules more susceptible to aggregation
into oligomers or ﬁbrils. Recent research shows that not
only phospholipid bilayers, but also a polyanion like heparin
[80] or a dichloromethane/water interface [22] can induce
nucleation and aggregation of hIAPP. These results indicate
that charge and a hydrophobic/hydrophilic interface (both
present in biological membranes) are important factors that
promote hIAPP ﬁbril formation.
6. FUTURE PERSPECTIVES AND CHALLENGES
During the last years, the understanding of hIAPP-mem-
brane interactions has signiﬁcantly increased. We have now
important indications that oligomeric hIAPP, in contrast
to ﬁbrillar hIAPP, is the main species involved in mem-
brane damage and is a likely candidate to cause β-cell
death in DM2. However, in a cellular environment, such
toxic oligomers have not (yet) been directly demonstrated.
More insight is required into the question whether hIAPP
oligomers are inherently cytotoxic and persist as toxic
oligomer after their cytotoxic action, or whether they
are transient participants in the process of ﬁbril growth
at the membrane. A major challenge is to elucidate the
mechanism by which hIAPP induces membrane damage
and cytotoxicity. This knowledge would be essential to
develop new strategies to battle hIAPP-induced β-cell death
in DM2. Determination of the three-dimensional structure
of membrane disrupting hIAPP would be an important
contribution in elucidation of the cytotoxic mechanism.
Moreover, the importance of hIAPP-membrane interactions,
discussed here, indicates that inhibition or alteration of
hIAPP-membrane interactions might be an alternative
strategy to reduce amyloid cytotoxicity and to prevent β-cell
death in DM2, in addition to the “traditional strategy” to
reduce amyloid by the development of molecules that inhibit
amyloid ﬁbril formation.
ACKNOWLEDGMENTS
This research was ﬁnancially supported by the Dutch
Diabetes Research Foundation (Grant no. 2002.00.019).
Lucie Khemt´ emourian was supported by the European
Commission (Marie Curie Postdoctoral fellowship).
REFERENCES
[1] P. Westermark, “Fine structure of islets of Langerhans in
insular amyloidosis,” Virchows Archiv A, vol. 359, no. 1, pp.
1–18, 1973.
[ 2 ]P .W e s t e r m a r k ,C .W e r n s t e d t ,E .W i l a n d e r ,D .W .H a y d e n ,T .
D. O’Brien, and K. H. Johnson, “Amyloid ﬁbrils in human
insulinoma and islets of Langerhans of the diabetic cat are
derived from a neuropeptide-like protein also present in
normal islet cells,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 84, no. 11, pp.
3881–3885, 1987.
[ 3 ]G .J .S .C o o p e r ,A .C .W i l l i s ,A .C l a r k ,R .C .T u r n e r ,R .B .
Sim, and K. B. M. Reid, “Puriﬁcation and characterization
of a peptide from amyloid-rich pancreases of type 2 diabetic
patients,” Proceedingsof the National Academy of Sciencesof the
United States of America, vol. 84, no. 23, pp. 8628–8632, 1987.
[ 4 ] A .C l a r k ,C .E .L e wi s ,A .C .W i l l i s ,e ta l . ,“ I s l e ta m y l o i df o r m e d
from diabetes-associated peptide may be pathogenic in type-2
diabetes,” The Lancet, vol. 330, no. 8553, pp. 231–234, 1987.
[5] A. Lorenzo, B. Razzaboni, G. C. Weir, and B. A. Yankner,
“Pancreatic islet cell toxicity of amylin associated with type-
2 diabetes mellitus,” Nature, vol. 368, no. 6473, pp. 756–760,
1994.
[ 6 ]T .D .O ’ B r i e n ,P .C .B u t l e r ,D .K .K r e u t t e r ,L .A .K a n e ,a n dN .
L. Eberhardt, “Human islet amyloid polypeptide expression
in COS-1 cells. A model of intracellular amyloidogenesis,”
American Journal of Pathology, vol. 147, no. 3, pp. 609–616,
1995.
[7] J. Janson, R. H. Ashley, D. Harrison, S. McIntyre, and P. C.
Butler, “The mechanism of islet amyloid polypeptide toxicity
is membrane disruption by intermediate-sized toxic amyloid
particles,” Diabetes, vol. 48, no. 3, pp. 491–498, 1999.
[8] H. J. Hiddinga and N. L. Eberhardt, “Intracellular amyloido-
genesis by human islet amyloid polypeptide induces apoptosis
in COS-1 cells,” American Journal of Pathology, vol. 154, no. 4,
pp. 1077–1088, 1999.
[ 9 ]E .L .S a a ﬁ ,B .K o n a r k o w s k a ,S .Z h a n g ,J .K i s t l e r ,a n dG .J .
S. Cooper, “Ultrastructural evidence that apoptosis is the
mechanism by which human amylin evokes death in RINm5F
pancreatic islet β-cells,” Cell Biology International, vol. 25,
no. 4, pp. 339–350, 2001.
[10] C.Betsholtz,L.Christmansson,U.Engstr¨ om,etal.,“Sequence
divergence in a speciﬁc region of islet amyloid polypep-
tide (IAPP) explains diﬀerences in islet amyloid formation
between species,” FEBS Letters, vol. 251, no. 1-2, pp. 261–264,
1989.
[11] J. W. M. H¨ oppener, C. Oosterwijk, M. G. Nieuwenhuis, et al.,
“Extensive islet amyloid formation is induced by development
of type II diabetes mellitus and contributes to its progression:
pathogenesis of diabetes in a mouse model,” Diabetologia,
vol. 42, no. 4, pp. 427–434, 1999.
[12] P. Westermark, U. Engstr¨ o m ,K .H .J o h n s o n ,G .T .W e s t e r -
mark, and C. Betsholtz, “Islet amyloid polypeptide: pinpoint-
ing amino acid residues linked to amyloid ﬁbril formation,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 87, no. 13, pp. 5036–5040, 1990.
[13] S. B. P. Charg´ e, E. J. P. de Koning, and A. Clark, “Eﬀect of pH
and insulin on ﬁbrillogenesis of islet amyloid polypeptide in
vitro,” Biochemistry, vol. 34, no. 44, pp. 14588–14593, 1995.
[14] A. Kapurniotu, J. Bernhagen, N. Greenﬁeld, et al., “Contri-
bution of advanced glycosylation to the amyloidogenicity of
islet amyloid polypeptide,” European Journal of Biochemistry,
vol. 251, no. 1-2, pp. 208–216, 1998.Lucie Khemt´ emourian et al. 7
[15] R. Kayed, J. Bernhagen, N. Greenﬁeld, et al., “Conformational
transitions of islet amyloid polypeptide (IAPP) in amyloid
formation in vitro,” Journal of Molecular Biology, vol. 287,
no. 4, pp. 781–796, 1999.
[16] E. T. A. S. Jaikaran, C. E. Higham, L. C. Serpell, et al.,
“Identiﬁcation of a novel human islet amyloid polypeptide β-
sheet domain and factors inﬂuencing ﬁbrillogenesis,” Journal
of Molecular Biology, vol. 308, no. 3, pp. 515–525, 2001.
[17] S. B. Padrick and A. D. Miranker, “Islet amyloid polypeptide:
identiﬁcation of long-range contacts and local order on the
ﬁbrillogenesis pathway,” Journal of Molecular Biology, vol. 308,
no. 4, pp. 783–794, 2001.
[18] S. B. Padrick and A. D. Miranker, “Islet amyloid: phase
partitioning and secondary nucleation are central to the
mechanismofﬁbrillogenesis,”Biochemistry,vol.41,no.14,pp.
4694–4703, 2002.
[19] J. L. Larson, E. Ko, and A. D. Miranker, “Direct measurement
of islet amyloid polypeptide ﬁbrillogenesis by mass spectrom-
etry,” Protein Science, vol. 9, no. 2, pp. 427–431, 2000.
[20] B. W. Koo and A. D. Miranker, “Contribution of the intrinsic
disulﬁde to the assembly mechanism of islet amyloid,” Protein
Science, vol. 14, no. 1, pp. 231–239, 2005.
[21] J. A. Williamson and A. D. Miranker, “Direct detection of
transient α-helical states in islet amyloid polypeptide,” Protein
Science, vol. 16, no. 1, pp. 110–117, 2007.
[22] A. M. Ruschak and A. D. Miranker, “Fiber-dependent amyloid
formation as catalysis of an existing reaction pathway,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 104, no. 30, pp. 12341–12346, 2007.
[23] J.D.HarperandP.T.LansburyJr.,“Modelsofamyloidseeding
in Alzheimer’s disease and scrapie: mechanistic truths and
physiological consequences of the time-dependent solubility
of amyloid proteins,” Annual Review of Biochemistry, vol. 66,
pp. 385–407, 1997.
[24] H. Naiki, K. Higuchi, M. Hosokawa, and T. Takeda, “Flu-
orometric determination of amyloid ﬁbrils in vitro using
the ﬂuorescent dye, thioﬂavine T,” Analytical Biochemistry,
vol. 177, no. 2, pp. 244–249, 1989.
[25] L. R. McLean and A. Balasubramaniam, “Promotion of β-
structure by interaction of diabetes associated polypeptide
(amylin) with phosphatidylcholine,” Biochimica et Biophysica
Acta, vol. 1122, no. 3, pp. 317–320, 1992.
[26] C. Goldsbury, K. Goldie, J. Pellaud, et al., “Amyloid ﬁbril
formation from full-length and fragments of amylin,” Journal
of Structural Biology, vol. 130, no. 2-3, pp. 352–362, 2000.
[27] S. A. Jayasinghe and R. Langen, “Lipid membranes modulate
the structure of islet amyloid polypeptide,” Biochemistry,
vol. 44, no. 36, pp. 12113–12119, 2005.
[28] J. D. Knight, J. A. Hebda, and A. D. Miranker, “Conserved and
cooperative assembly of membrane-bound α-helical states of
islet amyloid polypeptide,” Biochemistry, vol. 45, no. 31, pp.
9496–9508, 2006.
[29] M. Anguiano, R. J. Nowak, and P. T. Lansbury Jr., “Protoﬁbril-
lar islet amyloid polypeptide permeabilizes synthetic vesicles
by a pore-like mechanism that may be relevant to type II
diabetes,”Biochemistry,vol.41,no.38,pp.11338–11343,2002.
[30] J. D. Green, C. Goldsbury, J. Kistler, G. J. S. Cooper, and U.
Aebi, “Human amylin oligomer growth and ﬁbril elongation
deﬁne two distinct phases in amyloid formation,” Journal of
Biological Chemistry, vol. 279, no. 13, pp. 12206–12212, 2004.
[31] R. Kayed, Y. Sokolov, B. Edmonds, et al., “Permeabilization of
lipid bilayers is a common conformation-dependent activity
of soluble amyloid oligomers in protein misfolding diseases,”
Journal of Biological Chemistry, vol. 279, no. 45, pp. 46363–
46366, 2004.
[32] J.-C. Rochet, K. A. Conway, and P. T. Lansbury Jr., “Inhibition
of ﬁbrillization and accumulation of preﬁbrillar oligomers in
mixtures of human and mouse α-synuclein,” Biochemistry,
vol. 39, no. 35, pp. 10619–10626, 2000.
[33] C. G. Glabe and R. Kayed, “Common structure and toxic
function of amyloid oligomers implies a common mechanism
of pathogenesis,” Neurology, vol. 66, no. 2, supplement 1, pp.
S74–S78, 2006.
[34] R. Kayed, E. Head, J. L. Thompson, et al., “Common structure
of soluble amyloid oligomers implies common mechanism of
pathogenesis,” Science, vol. 300, no. 5618, pp. 486–489, 2003.
[35] C. Goldsbury, G. J. S. Cooper, K. N. Goldie, et al., “Polymor-
phic ﬁbrillar assembly of human amylin,” Journal of Structural
Biology, vol. 119, no. 1, pp. 17–27, 1997.
[36] O. Sumner Makin and L. C. Serpell, “Structural characterisa-
tion of islet amyloid polypeptide ﬁbrils,” Journal of Molecular
Biology, vol. 335, no. 5, pp. 1279–1288, 2004.
[37] S.A.JayasingheandR.Langen,“Identifyingstructuralfeatures
of ﬁbrillar islet amyloid polypeptide using site-directed spin
labeling,” Journal of Biological Chemistry, vol. 279, no. 46, pp.
48420–48425, 2004.
[38] M. R. Sawaya, S. Sambashivan, R. Nelson, et al., “Atomic
structures of amyloid cross-β spines reveal varied steric
zippers,” Nature, vol. 447, no. 7143, pp. 453–457, 2007.
[39] D. F. Moriarty and D. P. Raleigh, “Eﬀects of sequential proline
substitutions on amyloid formation by human amylin20−29,”
Biochemistry, vol. 38, no. 6, pp. 1811–1818, 1999.
[40] D. T. S. Rijkers, J. W. M. H¨ o p p e n e r ,G .P o s t h u m a ,C .J .M .
Lips, and R. M. J. Liskamp, “Inhibition of amyloid ﬁbril
formation of human amylin by N-alkylated amino acid and
α-hydroxy acid residue containing peptides,” Chemistry: A
European Journal, vol. 8, no. 18, pp. 4285–4291, 2002.
[41] Y. Porat, Y. Mazor, S. Efrat, and E. Gazit, “Inhibition of
islet amyloid polypeptide ﬁbril formation: a potential role for
heteroaromatic interactions,” Biochemistry, vol. 43, no. 45, pp.
14454–14462, 2004.
[42] L.-M. Yan, M. Tatarek-Nossol, A. Velkova, A. Kazantzis, and
A. Kapurniotu, “Design of a mimic of nonamyloidogenic
and bioactive human islet amyloid polypeptide (IAPP) as
nanomolaraﬃnityinhibitorofIAPPcytotoxicﬁbrillogenesis,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 103, no. 7, pp. 2046–2051, 2006.
[43] A. Abedini, F. Meng, and D. P. Raleigh, “A single-point
mutation converts the highly amyloidogenic human islet
amyloid polypeptide into a potent ﬁbrillization inhibitor,”
Journal of the American Chemical Society, vol. 129, no. 37, pp.
11300–11301, 2007.
[44] R. Azriel and E. Gazit, “Analysis of the minimal amyloid-
forming fragment of the islet amyloid polypeptide—an
experimental support for the key role of the phenylalanine
residue in amyloid formation,” Journal of Biological Chemistry,
vol. 276, no. 36, pp. 34156–34161, 2001.
[45] P. Marek, A. Abedini, B. Song, et al., “Aromatic interactions
are not required for amyloid ﬁbril formation by islet amyloid
polypeptide but do inﬂuence the rate of ﬁbril formation and
ﬁbril morphology,” Biochemistry, vol. 46, no. 11, pp. 3255–
3261, 2007.
[46] Y. Mazor, S. Gilead, I. Benhar, and E. Gazit, “Identiﬁcation
and characterization of a novel molecular-recognition and8 Experimental Diabetes Research
self-assembly domain within the islet amyloid polypeptide,”
Journal of Molecular Biology, vol. 322, no. 5, pp. 1013–1024,
2002.
[47] L. A. Scrocchi, K. Ha, Y. Chen, L. Wu, F. Wang, and P. E.
Fraser,“Identiﬁcationofminimalpeptidesequencesinthe(8–
20) domain of human islet amyloid polypeptide involved in
ﬁbrillogenesis,” Journal of Structural Biology, vol. 141, no. 3,
pp. 218–227, 2003.
[48] A. Abedini and D. P. Raleigh, “The role of His-18 in amyloid
formation by human islet amyloid polypeptide,” Biochemistry,
vol. 44, no. 49, pp. 16284–16291, 2005.
[49] A. Clark and M. R. Nilsson, “Islet amyloid: a complication of
islet dysfunction or an aetiological factor in type 2 diabetes?”
Diabetologia, vol. 47, no. 2, pp. 157–169, 2004.
[50] J. D. Knight and A. D. Miranker, “Phospholipid catalysis
of diabetic amyloid assembly,” Journal of Molecular Biology,
vol. 341, no. 5, pp. 1175–1187, 2004.
[51] E. Sparr, M. F. M. Engel, D. V. Sakharov, et al., “Islet amyloid
polypeptide-induced membrane leakage involves uptake of
lipids by forming amyloid ﬁbers,” FEBS Letters, vol. 577, no. 1-
2, pp. 117–120, 2004.
[52] D. H. J. Lopes, A. Meister, A. Gohlke, A. Hauser, A. Blume,
and R. Winter, “Mechanism of islet amyloid polypeptide
ﬁbrillation at lipid interfaces studied by infrared reﬂection
absorption spectroscopy,” Biophysical Journal,v o l .9 3 ,n o .9 ,
pp. 3132–3141, 2007.
[53] A. Quist, I. Doudevski, H. Lin, et al., “Amyloid ion channels:
a common structural link for protein-misfolding disease,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 102, no. 30, pp. 10427–10432, 2005.
[54] M. F. M. Engel, H. Yigittop, R. C. Elgersma, et al., “Islet
amyloid polypeptide inserts into phospholipid monolayers as
monomer,” Journal of Molecular Biology, vol. 356, no. 3, pp.
783–789, 2006.
[55] N. Arispe, H. B. Pollard, and E. Rojas, “Giant multilevel
cation channels formed by Alzheimer disease amyloid β-
protein [AβP-(1–40)] in bilayer membranes,” Proceedings of
the National Academy of Sciences of the United States of
America, vol. 90, no. 22, pp. 10573–10577, 1993.
[56] N. Arispe, H. B. Pollard, and E. Rojas, “The ability of amyloid
β-protein [AβP (1–40)] to form Ca
2+ channels provides a
mechanism for neuronal death in Alzheimer’s disease,” Annals
of the New York Academy of Sciences, vol. 747, pp. 256–266,
1994.
[57] T.A.Mirzabekov,M.-C.Lin,andB.L.Kagan,“Poreformation
by the cytotoxic islet amyloid peptide amylin,” Journal of
Biological Chemistry, vol. 271, no. 4, pp. 1988–1992, 1996.
[58] B. Konarkowska, J. F. Aitken, J. Kistler, S. Zhang, and G.
J. S. Cooper, “The aggregation potential of human amylin
determines its cytotoxicity towards islet β-cells,” FEBS Journal,
vol. 273, no. 15, pp. 3614–3624, 2006.
[ 5 9 ]A .D e m u r o ,E .M i n a ,R .K a y e d ,S .C .M i l t o n ,I .P a r k e r ,a n dC .
G. Glabe, “Calcium dysregulation and membrane disruption
as a ubiquitous neurotoxic mechanism of soluble amyloid
oligomers,” Journal of Biological Chemistry, vol. 280, no. 17,
pp. 17294–17300, 2005.
[60] Y. Porat, S. Kolusheva, R. Jelinek, and E. Gazit, “The human
islet amyloid polypeptide forms transient membrane-active
preﬁbrillar assemblies,” Biochemistry, vol. 42, no. 37, pp.
10971–10977, 2003.
[61] K. Balali-Mood, R. H. Ashley, T. Hauß, and J. P. Bradshaw,
“Neutron diﬀraction reveals sequence-speciﬁc membrane
insertion of pre-ﬁbrillar islet amyloid polypeptide and inhi-
bition by rifampicin,” FEBS Letters, vol. 579, no. 5, pp. 1143–
1148, 2005.
[62] T. A. Harroun, J. P. Bradshaw, and R. H. Ashley, “Inhibitors
can arrest the membrane activity of human islet amyloid
polypeptide independently of amyloid formation,” FEBS Let-
ters, vol. 507, no. 2, pp. 200–204, 2001.
[63] J. D. Green, L. Kreplak, C. Goldsbury, et al., “Atomic force
microscopy reveals defects within mica supported lipid bilay-
ers induced by the amyloidogenic human amylin peptide,”
JournalofMolecularBiology,vol.342,no.3,pp.877–887,2004.
[64] J. J. Meier, R. Kayed, C.-Y. Lin, et al., “Inhibition of human
IAPP ﬁbril formation does not prevent β-cell death: evidence
for distinct actions of oligomers and ﬁbrils of human IAPP,”
American Journal of Physiology, vol. 291, no. 6, pp. E1317–
E1324, 2006.
[65] M. Bucciantini, E. Giannoni, F. Chiti, et al., “Inherent toxicity
of aggregates implies a common mechanism for protein
misfolding diseases,” Nature, vol. 416, no. 6880, pp. 507–511,
2002.
[66] J. I. Kourie, A. L. Culverson, P. V. Farrelly, C. L. Henry,
and K. N. Laohachai, “Heterogeneous amyloid-formed ion
channels as a common cytotoxic mechanism: implications for
therapeutic strategies against amyloidosis,” Cell Biochemistry
and Biophysics, vol. 36, no. 2-3, pp. 191–207, 2002.
[67] J. R. Brender, U. H. N. D¨ urr, D. Heyl, M. B. Budarapu, and
A.Ramamoorthy,“Membranefragmentationbyanamyloido-
genic fragment of human islet amyloid polypeptide detected
by solid-state NMR spectroscopy of membrane nanotubes,”
Biochimica et Biophysica Acta, vol. 1768, no. 9, pp. 2026–2029,
2007.
[68] C.-J. Huang, C.-Y. Lin, L. Haataja, et al., “High expression
rates of human islet amyloid polypeptide induce endoplasmic
reticulum stress-mediated β-cell apoptosis, a characteristic of
humans with type 2 but not type 1 diabetes,” Diabetes, vol. 56,
no. 8, pp. 2016–2027, 2007.
[69] C.-Y. Lin, T. Gurlo, R. Kayed, et al., “Toxic human islet
amyloidpolypeptide(h-IAPP)oligomersareintracellular,and
vaccination to induce anti-toxic oligomer antibodies does not
preventh-IAPP-inducedβ-cellapoptosisinh-IAPPtransgenic
mice,” Diabetes, vol. 56, no. 5, pp. 1324–1332, 2007.
[70] S. Andrikopoulos, C. B. Verchere, J. C. Teague, et al., “Two
novel immortal pancreatic β-cell lines expressing and secret-
ing human islet amyloid polypeptide do not spontaneously
develop islet amyloid,” Diabetes, vol. 48, no. 10, pp. 1962–
1970, 1999.
[71] M. F. M. Engel, L. Kh´ emtemourian, C. Kleijer, et al., “Mem-
brane damage by human islet amyloid polypeptide through
ﬁbril growth at the membrane,” Proceedings of the National
Academy of Sciences of the United States of America. In press.
[72] M.Wogulis,S.Wright,D.Cunningham,T.Chilcote,K.Powell,
and R. E. Rydel, “Nucleation-dependent polymerization is
an essential component of amyloid-mediated neuronal cell
death,” Journal of Neuroscience, vol. 25, no. 5, pp. 1071–1080,
2005.
[73] H. Zhao, A. Jutila, T. Nurminen, S. A. Wickstr¨ om, J. Keski-
Oja, and P. K. J. Kinnunen, “Binding of endostatin to
phosphatidylserine-containing membranes and formation of
amyloid-like ﬁbers,” Biochemistry, vol. 44, no. 8, pp. 2857–
2863, 2005.
[74] H.Zhao,E.K.J.Tuominen,andP.K.J.Kinnunen,“Formation
of amyloid ﬁbers triggered by phosphatidylserine-containingLucie Khemt´ emourian et al. 9
membranes,” Biochemistry, vol. 43, no. 32, pp. 10302–10307,
2004.
[75] G. P. Gellermann, T. R. Appel, A. Tannert, et al., “Raft lipids as
common components of human extracellular amyloid ﬁbrils,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 102, no. 18, pp. 6297–6302, 2005.
[76] S. Gilead, H. Wolfenson, and E. Gazit, “Molecular mapping of
the recognition interface between the islet amyloid polypep-
tide and insulin,” Angewandte Chemie International Edition,
vol. 45, no. 39, pp. 6476–6480, 2006.
[77] P. Westermark, Z.-C. Li, G. T. Westermark, A. Leckstr¨ om,
a n dD .F .S t e i n e r ,“ E ﬀects of β cell granule components
on human islet amyloid polypeptide ﬁbril formation,” FEBS
Letters, vol. 379, no. 3, pp. 203–206, 1996.
[78] E.T. A. S. Jaikaran, M.R. Nilsson, and A. Clark,“Pancreatic β-
cell granule peptides form heteromolecular complexes which
inhibit islet amyloid polypeptide ﬁbril formation,” Biochemi-
cal Journal, vol. 377, part 3, pp. 709–716, 2004.
[79] I. Rustenbeck, A. Matthies, and S. Lenzen, “Lipid composition
of glucose-stimulated pancreatic islets and insulin-secreting
tumor cells,” Lipids, vol. 29, no. 10, pp. 685–692, 1994.
[80] T. Konno, S. Oiki, and T. Morii, “Synergistic action of
polyanionic and non-polar cofactors in ﬁbrillation of human
islet amyloid polypeptide,” FEBS Letters, vol. 581, no. 8, pp.
1635–1638, 2007.